This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	Epstein-Barr nuclear antigen 3B (EBNA3B)	<p>Mouse and patient sample studies suggest increasing EBNA3B signaling could help prevent Epstein-Barr virus (EBV)-associated lymphoma. In humanized mice, infection with an <i>Ebna3b</i> knockout EBV strain resulted in tumor formation and greater B cell expansion than infection with an <i>Ebna3b</i>-expressing strain. B cells derived from two patients with post-transplant lymphoproliferative disease had <i>EBNA3B</i> mutations. Next steps could include identifying a pharmacological agent that increases EBNA3B signaling and developing a diagnostic to screen patients for infection with <i>Ebna3b</i>-mutant EBV.</p> <p>SciBX 5(13); doi:10.1038/scibx.2012.334 Published online March 29, 2012</p>	Patent and licensing status unavailable	<p>White, R.E. <i>et al.</i> <i>J. Clin. Invest.</i>; published online March 12, 2012; doi:10.1172/JCI58092</p> <p>Contact: Martin J. Allday, Imperial College London, London, U.K. e-mail: m.allday@imperial.ac.uk</p>